# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Andrew Fein reiterates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and maintains $80 pri...
Corbus Pharmaceuticals (NASDAQ:CRBP) reported quarterly losses of $(0.90) per share which beat the analyst consensus estimate o...
GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards exome/genome testing and r...
GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards exome/genome testing and r...